Weekly docetaxel and cisplatin plus fluorouracil as a preoperative treatment for gastric cancer patients with synchronous multiple hepatic metastases: A pilot study

Medical Oncology

Volumn 27, Issue 4, 2010, Pages 1314-1318

  Li, Zi Yu ^a   Tang, Lei ^a   Zhang, Lian Hai ^a   Bu, Zhao De ^a   Wu, Ai Wen ^a   Wu, Xiao Jiang ^a   Zong, Xiang Long ^a   Wu, Qi ^a   Shan, Fei ^a   Li, Shuang Xi ^a   Ren, Hui ^a   Zhang, Xiao Peng ^a   Ji, Jia Fu ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Gastric cancer; Liver metastasis; Preoperative chemotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; MALE; NAUSEA; NEUTROPENIA; PILOT STUDY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; STOMACH CANCER; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; PREOPERATIVE CARE; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 79551693463     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9381-y     Document Type: Article

References (20)

1. Okuyama K, Isono K, Juan IK, et al. Evaluation of treatment for gastric cancer with liver metastasis. Cancer. 1985;55:2498-505. (Pubitemid 15115205)
2. Sakamoto Y, Ohyama S, Yamamoto J, et al. Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery. 2003;133:507-11. (Pubitemid 36638222)
3. Nomura T, Kamio Y, Takasu N, et al. Intrahepatic micrometastases around liver metastases from gastric cancer. J Hepatobiliary Pancreat Surg. 2009;16:493-501.
4. Mavroudis D, Kourousis C, Androulakis N, et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol. 2000;23:341-4. (Pubitemid 32429142)
5. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005;23:5660-7.
6. Roth AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007;25:3217-23. (Pubitemid 47325604)
7. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-7. (Pubitemid 46631401)
8. Camps C, Massuti B, Jimenez A, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol. 2006;17:467-72. (Pubitemid 43329585)
9. Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol. 2005;23:8389-95.
10. Ojima H, Ootake S, Yokobori T et al. Treatment of multiple liver metastasis from gastric carcinoma. World J Surg Oncol 2007;5:70.
11. Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg. 1981;11:127-39. (Pubitemid 11080134)
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
13. Kakeji Y, Maehara Y, Tomoda M, et al. Long-term survival of patients with stage IV gastric carcinoma. Cancer. 1998;82:2307-11. (Pubitemid 28283435)
14. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of US gastric carcinoma patients treated with gastrectomy: fifth edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer. 2000;88:921-32. (Pubitemid 30091113)
15. Ambiru S, Miyazaki M, Ito H, et al. Benefits and limits of hepatic resection for gastric metastases. Am J Surg. 2001;181:279-83. (Pubitemid 32480231)
16. Okano K, Maeba T, Ishimura K, et al. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg. 2002;235:86-91. (Pubitemid 34062403)
17. Elias D, Cavalcanti de Albuquerque A, Eggenspieler P, et al. Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg. 1998;187:487-93. (Pubitemid 28506854)
18. Ueda K, Iwahashi M, Nakamori M, et al. Analysis of the prognostic factors and evaluation of surgical treatment for synchronous liver metastases from gastric cancer. Langenbecks Arch Surg. 2009;394:647-53.
19. Okuyama K, Onoda S, Tohnosu N, et al. The prognostic significance of resection of primary tumor in gastric and colorectal cancer patients with synchronous liver metastasis. Jpn J Surg. 1988;18:7-17.
20. Hoffmann RT, Jakobs TF, Kubisch CH et al. Radiofrequency ablation after selective internal radiation therapy with Yttrium90 microspheres in metastatic liver disease-Is it feasible? Eur J Radiol 2009.